BAC
Bank of America Corporation
BAC has slightly lower modeled downside risk, despite its lower overall score.
NKSH
National Bankshares, Inc.
NKSH has the edge over BAC overall, supported by stronger fundamentals and stronger valuation.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
NKSH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
NKSH's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like NKSH.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC has the edge over NKSH in the historical PE scenario, which offers more potential upside but is not a forecast.
NKSH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.6x | $32.39 | -18% |
| Forward | 10x | $39.59 | — |
| Current | 12x | $39.59 | — |
| Fair | 13x | $42.43 | +7.2% |
| Expensive | 17x | $56.42 | +42% |
Historical ranges are pointers, not guarantees.
NKSH's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for BAC, with profitability improving.
NKSH Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for NKSH, with profitability improving.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC's earnings per share have climbed steadily: $4.19 over the past year, up 14% from the year before, and higher year over year for eight quarters in a row.
NKSH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.85 | +15% |
| Q3 2026 | $3.36 | +63% |
| Q2 2026 | $3.19 | +78% |
| Q1 2026 | $2.76 | +100% |
| Q4 2025 | $2.49 | +101% |
| Q3 2025 | $2.06 | +42% |
| Q2 2025 | $1.79 | +15% |
| Q1 2025 | $1.38 | -39% |
| Q4 2024 | $1.24 | -53% |
NKSH earned $3.36 per share over the past year, up 63% from the year before.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC's revenue has grown year over year for 10 quarters in a row: $30B last quarter, up 6.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
NKSH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $16.4M | +16% |
| Q2 2026 | $15.7M | +18% |
| Q1 2026 | $15.3M | +19% |
| Q4 2025 | $15.3M | +25% |
| Q3 2025 | $14.2M | +21% |
| Q2 2025 | $13.3M | +21% |
| Q1 2025 | $12.8M | +23% |
| Q4 2024 | $12.2M | +14% |
NKSH has the edge over BAC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 41% | +3.4 points |
| Q2 2026 | 39% | +19 points |
| Q1 2026 | 40% | +9.1 points |
| Q4 2025 | 47% | +17 points |
| Q3 2025 | 38% | +10 points |
| Q2 2025 | 20% | +24 points |
| Q1 2025 | 30% | +4.7 points |
| Q4 2024 | 30% | -17 points |
NKSH has the edge over BAC on profitability, with a higher operating margin.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
NKSH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $7.1M | +33% |
| Q2 2026 | $3.3M | +118% |
| Q1 2026 | $3.1M | +92% |
| Q4 2025 | $6.7M | +50% |
| Q2 2025 | $1.5M | +$4.5M |
| Q1 2025 | $1.6M | -58% |
| Q2 2024 | -$2.9M | -173% |
| Q1 2024 | $3.8M | -11% |
NKSH has the edge over BAC on cash flow, with more consistent year-over-year improvement.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over NKSH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
NKSH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +1.3K shares |
| 1 year | +0.1% | +5.1K shares |
| 3 years | +8.1% | +479K shares |
| 5 years | +3.7% | +226K shares |
| Available history | -3.2% | -212K shares |
NKSH has 6M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | $2.6M |
| Q3 2022 | $796,000 |
| Q2 2022 | $1.4M |
| Q1 2022 | $1.5M |
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
NKSH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.1x | Net Cash |
| Q2 2026 | -2.1x | Net Cash |
| Q1 2026 | -2.7x | Net Cash |
| Q4 2025 | -2.9x | Net Cash |
| Q3 2025 | -2.5x | Net Cash |
| Q2 2025 | -6.3x | Net Cash |
| Q1 2025 | -10.6x | Net Cash |
| Q4 2024 | -10.5x | Net Cash |
NKSH has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
NKSH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.8 | Neutral |
| Stochastic | 18.9 | Oversold |
NKSH's weekly RSI is 50 (neutral) and its Stochastic is 19 (oversold).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
NKSH PE vs Financial Services Sector
| Metric | NKSH | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 9.5% below |
| PE % | 42 | 63 | 21 pts below |
NKSH has the edge over BAC on valuation relative to its sector.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
NKSH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $41.3 | 4.2% below |
| 20 week MA | $40.6 | 2.4% below |
| 50 week MA | $37.7 | 5% above |
| 100 week MA | $32.9 | 20% above |
| 200 week MA | $31.8 | 25% above |
NKSH has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
NKSH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $46.1 | $31.7 | -31% |
| 2021 | $31.7 | $35.6 | +12% |
| 2022 | $35.6 | $39.8 | +12% |
| 2023 | $39.8 | $32.4 | -19% |
| 2024 | $32.4 | $28.4 | -12% |
| 2025 | $28.4 | $33.9 | +19% |
| 2026 YTD | $33.9 | $39.6 | +17% |
NKSH has the edge over BAC on returns for 2026, with the stronger performance.